Connect Biopharma (CNTB) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Connect Biopharma (CNTB).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | 170K | - | 20K (-60.00%) | 50K | - | 700K (-42.62%) | 1.22M (-94.94%) | 24M | - |
Operating Expenses | |||||||||
Research And Development | 15M (+33.24%) | 11M (+1.53%) | 11M (+26.68%) | 8.77M (+32.28%) | 6.63M (+6.25%) | 6.24M (-30.74%) | 9.01M (+68.41%) | 5.35M (-38.22%) | 8.66M |
Selling General And Administrative | 4.75M (+12.03%) | 4.24M (-35.56%) | 6.58M (+40.00%) | 4.70M (-2.29%) | 4.81M (+17.89%) | 4.08M (-32.67%) | 6.06M (+18.36%) | 5.12M (+28.97%) | 3.97M |
Operating Expenses | 20M (+27.37%) | 16M (-12.21%) | 18M (+31.33%) | 13M (+17.64%) | 11M (+10.95%) | 10M (-31.52%) | 15M (+43.94%) | 10M (-17.10%) | 13M |
Depreciation And Amortization | 160K (-69.81%) | 530K | - | - | 170K (-66.00%) | 500K | - | - | 160K |
Operating Income | |||||||||
Operating Income | -19.61M (+26.27%) | -15.53M (-12.16%) | -17.68M (+31.74%) | -13.42M (+17.21%) | -11.45M (+19.02%) | -9.62M (-30.54%) | -13.85M | 14M | -12.63M |
Ebit | -19.61M (+26.27%) | -15.53M (-12.16%) | -17.68M (+31.74%) | -13.42M (+17.21%) | -11.45M (+19.02%) | -9.62M (-30.54%) | -13.85M | 14M | -12.63M |
EBITDA | -19.44M (+20.67%) | -16.11M (-6.01%) | -17.14M (+33.49%) | -12.84M (+13.93%) | -11.27M (-0.97%) | -11.38M (-11.23%) | -12.82M | 15M | -12.47M |
Other Income / Expenses | |||||||||
Other Non Operating Income | - | 520K | -10.00K (-75.00%) | -40.00K | 510K (-80.31%) | 2.59M | -110.00K | 10K (-99.63%) | 2.72M |
Net Income | |||||||||
Income Before Tax | -19.35M (+28.32%) | -15.08M (-12.02%) | -17.14M (+33.49%) | -12.84M (+25.64%) | -10.22M (+16.14%) | -8.80M (-31.36%) | -12.82M | 15M | -8.66M |
Income Tax Expense | 50K (+66.67%) | 30K (-50.00%) | 60K (0.00%) | 60K (+20.00%) | 50K (-54.55%) | 110K (+83.33%) | 60K (+100.00%) | 30K (0.00%) | 30K |
Net Income From Continuing Operations | -19.40M (+28.39%) | -15.11M (-12.15%) | -17.20M (+33.33%) | -12.90M (+25.61%) | -10.27M (+15.26%) | -8.91M (-30.82%) | -12.88M | 15M | -8.69M |
Net Income | -19.40M (+28.39%) | -15.11M (-12.15%) | -17.20M (+33.33%) | -12.90M (+25.61%) | -10.27M (+15.26%) | -8.91M (-30.82%) | -12.88M | 15M | -8.69M |
Comprehensive Income Net Of Tax | -19.27M (-64.96%) | -55.00M (+221.64%) | -17.10M (+34.96%) | -12.67M (+24.09%) | -10.21M (-37.32%) | -16.29M (+32.33%) | -12.31M | 15M | -8.92M |